Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rectal Neoplasms | 16 | 2022 | 1179 | 1.430 |
Why?
|
Adenocarcinoma | 33 | 2023 | 6400 | 1.400 |
Why?
|
Pancreatic Neoplasms | 36 | 2023 | 5442 | 1.400 |
Why?
|
Liver Neoplasms | 26 | 2021 | 4362 | 1.120 |
Why?
|
Neoadjuvant Therapy | 22 | 2023 | 2896 | 1.080 |
Why?
|
Fluorouracil | 29 | 2023 | 1656 | 0.970 |
Why?
|
Cholangiocarcinoma | 9 | 2024 | 563 | 0.850 |
Why?
|
Bile Duct Neoplasms | 9 | 2024 | 617 | 0.850 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 35 | 2023 | 11843 | 0.820 |
Why?
|
Carcinoma, Pancreatic Ductal | 11 | 2023 | 1755 | 0.810 |
Why?
|
Carcinoma, Hepatocellular | 17 | 2019 | 2331 | 0.770 |
Why?
|
Colorectal Neoplasms | 15 | 2022 | 6978 | 0.640 |
Why?
|
Anus Neoplasms | 6 | 2020 | 338 | 0.620 |
Why?
|
Hepatectomy | 7 | 2020 | 588 | 0.600 |
Why?
|
Yttrium Radioisotopes | 1 | 2017 | 114 | 0.530 |
Why?
|
Leucovorin | 12 | 2023 | 643 | 0.520 |
Why?
|
Deoxycytidine | 17 | 2018 | 888 | 0.510 |
Why?
|
Neuroendocrine Tumors | 7 | 2021 | 649 | 0.500 |
Why?
|
Gastrointestinal Neoplasms | 5 | 2023 | 959 | 0.440 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2021 | 736 | 0.430 |
Why?
|
Positron-Emission Tomography | 12 | 2022 | 6657 | 0.410 |
Why?
|
Radiopharmaceuticals | 6 | 2022 | 2731 | 0.410 |
Why?
|
Salvage Therapy | 2 | 2017 | 1277 | 0.400 |
Why?
|
Pancreatectomy | 5 | 2023 | 824 | 0.380 |
Why?
|
Organoplatinum Compounds | 9 | 2019 | 408 | 0.370 |
Why?
|
Embolization, Therapeutic | 2 | 2019 | 1435 | 0.370 |
Why?
|
Camptothecin | 7 | 2017 | 594 | 0.360 |
Why?
|
Neoplasm Staging | 26 | 2022 | 11249 | 0.350 |
Why?
|
Esophageal Neoplasms | 6 | 2020 | 1676 | 0.350 |
Why?
|
Lymphopenia | 2 | 2024 | 290 | 0.350 |
Why?
|
Stomach Neoplasms | 6 | 2020 | 1484 | 0.340 |
Why?
|
Survival Rate | 23 | 2024 | 12875 | 0.330 |
Why?
|
Antineoplastic Agents | 18 | 2020 | 13708 | 0.320 |
Why?
|
Antimetabolites, Antineoplastic | 7 | 2014 | 647 | 0.320 |
Why?
|
Aged | 87 | 2024 | 171520 | 0.290 |
Why?
|
Middle Aged | 94 | 2024 | 223418 | 0.290 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2011 | 388 | 0.270 |
Why?
|
Disease-Free Survival | 17 | 2017 | 6856 | 0.260 |
Why?
|
Adrenalectomy | 1 | 2008 | 348 | 0.260 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2008 | 259 | 0.250 |
Why?
|
Retrospective Studies | 44 | 2024 | 81834 | 0.250 |
Why?
|
Neoplasm, Residual | 3 | 2021 | 1014 | 0.240 |
Why?
|
Male | 101 | 2024 | 364781 | 0.240 |
Why?
|
Aged, 80 and over | 41 | 2024 | 59680 | 0.220 |
Why?
|
Treatment Outcome | 39 | 2023 | 65409 | 0.220 |
Why?
|
Gene Amplification | 2 | 2020 | 1091 | 0.220 |
Why?
|
Female | 96 | 2024 | 396943 | 0.220 |
Why?
|
Photons | 2 | 2019 | 595 | 0.200 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 90 | 0.200 |
Why?
|
Humans | 126 | 2024 | 768451 | 0.200 |
Why?
|
Antibodies, Monoclonal | 13 | 2015 | 9263 | 0.200 |
Why?
|
Chemoembolization, Therapeutic | 2 | 2013 | 129 | 0.200 |
Why?
|
Kaplan-Meier Estimate | 13 | 2020 | 6537 | 0.190 |
Why?
|
Fluorodeoxyglucose F18 | 8 | 2022 | 2048 | 0.190 |
Why?
|
Coronary Vasospasm | 1 | 2022 | 81 | 0.190 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 224 | 0.190 |
Why?
|
Pancreaticoduodenectomy | 4 | 2019 | 516 | 0.190 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2018 | 811 | 0.190 |
Why?
|
Quinazolines | 6 | 2014 | 1376 | 0.190 |
Why?
|
Radiodermatitis | 2 | 2019 | 61 | 0.180 |
Why?
|
Sirolimus | 4 | 2013 | 1542 | 0.180 |
Why?
|
Peritoneal Neoplasms | 2 | 2022 | 715 | 0.180 |
Why?
|
Adult | 61 | 2024 | 223542 | 0.180 |
Why?
|
Esophagogastric Junction | 2 | 2020 | 349 | 0.170 |
Why?
|
Biliary Tract Neoplasms | 2 | 2014 | 187 | 0.170 |
Why?
|
Prognosis | 22 | 2024 | 30028 | 0.170 |
Why?
|
Radiotherapy Dosage | 11 | 2019 | 2925 | 0.170 |
Why?
|
Neuroblastoma | 1 | 2008 | 1265 | 0.170 |
Why?
|
Gallbladder Neoplasms | 2 | 2014 | 191 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2019 | 9425 | 0.160 |
Why?
|
Radiotherapy | 4 | 2021 | 1510 | 0.160 |
Why?
|
Carcinoid Tumor | 2 | 2011 | 226 | 0.160 |
Why?
|
Mitomycin | 5 | 2019 | 264 | 0.160 |
Why?
|
Doxorubicin | 3 | 2013 | 2229 | 0.160 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 6 | 2015 | 1766 | 0.150 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2015 | 954 | 0.150 |
Why?
|
Intraoperative Care | 2 | 2019 | 772 | 0.150 |
Why?
|
Gastrinoma | 1 | 2017 | 21 | 0.150 |
Why?
|
Losartan | 1 | 2019 | 263 | 0.140 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2020 | 4083 | 0.140 |
Why?
|
Feasibility Studies | 4 | 2023 | 5308 | 0.140 |
Why?
|
Pelvic Bones | 2 | 2017 | 270 | 0.140 |
Why?
|
Treatment Refusal | 1 | 2020 | 432 | 0.140 |
Why?
|
Liver Failure | 1 | 2019 | 252 | 0.140 |
Why?
|
DNA, Neoplasm | 2 | 2019 | 1749 | 0.130 |
Why?
|
Combined Modality Therapy | 12 | 2022 | 8559 | 0.130 |
Why?
|
Cancer Care Facilities | 1 | 2019 | 424 | 0.130 |
Why?
|
Magnetic Resonance Imaging | 9 | 2022 | 36840 | 0.130 |
Why?
|
Genetic Heterogeneity | 2 | 2019 | 738 | 0.130 |
Why?
|
Healthcare Disparities | 2 | 2023 | 3412 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2020 | 568 | 0.130 |
Why?
|
Laparotomy | 1 | 2018 | 459 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2022 | 3550 | 0.130 |
Why?
|
ras Proteins | 4 | 2014 | 1058 | 0.130 |
Why?
|
Colonic Neoplasms | 2 | 2020 | 2544 | 0.120 |
Why?
|
Lymph Nodes | 3 | 2019 | 3472 | 0.120 |
Why?
|
Bone Marrow Diseases | 1 | 2017 | 234 | 0.120 |
Why?
|
Mutation | 9 | 2020 | 30243 | 0.120 |
Why?
|
Rectum | 1 | 2019 | 902 | 0.120 |
Why?
|
Neutropenia | 2 | 2017 | 892 | 0.120 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2019 | 5342 | 0.120 |
Why?
|
Bile Ducts, Intrahepatic | 3 | 2014 | 304 | 0.110 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2015 | 333 | 0.110 |
Why?
|
Angiogenesis Inhibitors | 3 | 2010 | 2062 | 0.110 |
Why?
|
Spermine | 1 | 2013 | 70 | 0.110 |
Why?
|
Follow-Up Studies | 14 | 2024 | 39430 | 0.110 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 1995 | 249 | 0.110 |
Why?
|
Survival Analysis | 12 | 2019 | 10125 | 0.110 |
Why?
|
Neoplasm Metastasis | 7 | 2020 | 4931 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 9 | 2021 | 20762 | 0.100 |
Why?
|
Dacarbazine | 2 | 2013 | 560 | 0.100 |
Why?
|
Blood Vessels | 1 | 2018 | 1112 | 0.100 |
Why?
|
Capsules | 1 | 2013 | 193 | 0.100 |
Why?
|
Tretinoin | 1 | 1995 | 525 | 0.100 |
Why?
|
Glutarates | 1 | 2014 | 243 | 0.100 |
Why?
|
Indoles | 2 | 2011 | 1834 | 0.100 |
Why?
|
Radiation Injuries | 2 | 2017 | 1205 | 0.100 |
Why?
|
Cisplatin | 4 | 2010 | 1661 | 0.100 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2014 | 423 | 0.100 |
Why?
|
beta Karyopherins | 1 | 2011 | 46 | 0.090 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 1680 | 0.090 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1103 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2019 | 2072 | 0.090 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2012 | 750 | 0.090 |
Why?
|
Mesentery | 1 | 2011 | 202 | 0.090 |
Why?
|
Medical Oncology | 2 | 2021 | 2347 | 0.090 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 952 | 0.090 |
Why?
|
Multimedia | 1 | 2010 | 76 | 0.080 |
Why?
|
Phenylurea Compounds | 1 | 2013 | 532 | 0.080 |
Why?
|
Thrombosis | 1 | 2023 | 2956 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2012 | 1794 | 0.080 |
Why?
|
Arsenicals | 1 | 2009 | 117 | 0.080 |
Why?
|
Triazoles | 1 | 2014 | 905 | 0.080 |
Why?
|
Vagina | 1 | 2014 | 845 | 0.080 |
Why?
|
Bone Marrow | 2 | 2017 | 2929 | 0.080 |
Why?
|
Drug Carriers | 1 | 2013 | 712 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 4 | 2014 | 4534 | 0.080 |
Why?
|
Carcinoembryonic Antigen | 2 | 2023 | 338 | 0.080 |
Why?
|
Lymphoma | 1 | 2017 | 1907 | 0.070 |
Why?
|
Radiosurgery | 1 | 2017 | 1354 | 0.070 |
Why?
|
Tubulin | 1 | 2011 | 695 | 0.070 |
Why?
|
Quinolines | 1 | 2013 | 769 | 0.070 |
Why?
|
Disease Progression | 7 | 2022 | 13655 | 0.070 |
Why?
|
Proportional Hazards Models | 6 | 2020 | 12561 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3665 | 0.070 |
Why?
|
Standard of Care | 2 | 2022 | 571 | 0.070 |
Why?
|
Anal Canal | 2 | 2020 | 376 | 0.070 |
Why?
|
Respiration | 1 | 2013 | 1667 | 0.070 |
Why?
|
Tumor Burden | 4 | 2017 | 1909 | 0.070 |
Why?
|
Chorioamnionitis | 1 | 2008 | 156 | 0.070 |
Why?
|
Glutathione | 1 | 2009 | 587 | 0.070 |
Why?
|
Radiography, Abdominal | 1 | 2010 | 541 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2008 | 369 | 0.060 |
Why?
|
Quality of Life | 3 | 2023 | 13497 | 0.060 |
Why?
|
Intestine, Small | 1 | 2012 | 1218 | 0.060 |
Why?
|
Radiology Information Systems | 1 | 2010 | 533 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4120 | 0.060 |
Why?
|
Catheter Ablation | 1 | 2019 | 2775 | 0.060 |
Why?
|
Colectomy | 1 | 2010 | 700 | 0.060 |
Why?
|
Prospective Studies | 10 | 2021 | 54914 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 2067 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5887 | 0.060 |
Why?
|
Lamivudine | 2 | 2022 | 368 | 0.060 |
Why?
|
Maximum Tolerated Dose | 3 | 2013 | 890 | 0.060 |
Why?
|
Patient-Centered Care | 1 | 2014 | 1439 | 0.060 |
Why?
|
Pain | 3 | 2014 | 5096 | 0.060 |
Why?
|
Propensity Score | 2 | 2023 | 1971 | 0.060 |
Why?
|
Pregnancy Trimester, First | 1 | 2008 | 918 | 0.050 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1207 | 0.050 |
Why?
|
Estradiol | 1 | 2010 | 1949 | 0.050 |
Why?
|
Adenomatous Polyposis Coli Protein | 2 | 2014 | 182 | 0.050 |
Why?
|
Mesenteric Veins | 1 | 2023 | 87 | 0.050 |
Why?
|
Lymphatic Metastasis | 3 | 2019 | 2930 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1127 | 0.050 |
Why?
|
Abortion, Spontaneous | 1 | 2008 | 539 | 0.050 |
Why?
|
Cohort Studies | 7 | 2023 | 41797 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2022 | 2964 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 14728 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2020 | 2525 | 0.050 |
Why?
|
Massachusetts | 4 | 2020 | 8908 | 0.050 |
Why?
|
Intestines | 1 | 2011 | 1912 | 0.050 |
Why?
|
Laparoscopy | 2 | 2019 | 2056 | 0.050 |
Why?
|
Protein Kinases | 1 | 2008 | 1608 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2022 | 162 | 0.050 |
Why?
|
Multivariate Analysis | 4 | 2020 | 12096 | 0.050 |
Why?
|
Fractals | 1 | 2021 | 127 | 0.050 |
Why?
|
Hepatitis B, Chronic | 1 | 2005 | 413 | 0.050 |
Why?
|
Drug Administration Schedule | 4 | 2013 | 4861 | 0.040 |
Why?
|
Nitrates | 1 | 2022 | 260 | 0.040 |
Why?
|
Portal Vein | 1 | 2023 | 432 | 0.040 |
Why?
|
Physician-Patient Relations | 1 | 2014 | 3267 | 0.040 |
Why?
|
Carcinoma, Small Cell | 1 | 2003 | 420 | 0.040 |
Why?
|
GTP Phosphohydrolases | 2 | 2014 | 525 | 0.040 |
Why?
|
Cicatrix | 1 | 2006 | 799 | 0.040 |
Why?
|
Albumins | 1 | 2023 | 578 | 0.040 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2021 | 3783 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2021 | 240 | 0.040 |
Why?
|
Databases, Factual | 3 | 2019 | 8081 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 784 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 2023 | 643 | 0.040 |
Why?
|
Nitrosourea Compounds | 1 | 1998 | 32 | 0.040 |
Why?
|
Biopsy | 1 | 2011 | 6816 | 0.040 |
Why?
|
Edema | 1 | 2023 | 766 | 0.040 |
Why?
|
Colostomy | 1 | 2019 | 106 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2022 | 692 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 714 | 0.040 |
Why?
|
Young Adult | 7 | 2020 | 60045 | 0.040 |
Why?
|
Carbon-Carbon Ligases | 1 | 1997 | 19 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2011 | 13026 | 0.040 |
Why?
|
Cytotoxins | 1 | 1998 | 154 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2008 | 4249 | 0.040 |
Why?
|
Prothrombin | 1 | 1997 | 192 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2010 | 3629 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 5803 | 0.030 |
Why?
|
Pelvis | 1 | 2020 | 737 | 0.030 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2003 | 958 | 0.030 |
Why?
|
Radiography | 3 | 2012 | 6995 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1013 | 0.030 |
Why?
|
Paclitaxel | 1 | 2023 | 1737 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 783 | 0.030 |
Why?
|
Radiation Dosage | 2 | 2017 | 1973 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2005 | 2643 | 0.030 |
Why?
|
Vitamin K | 1 | 1997 | 314 | 0.030 |
Why?
|
Liver | 2 | 2014 | 7575 | 0.030 |
Why?
|
Age Factors | 3 | 2023 | 18478 | 0.030 |
Why?
|
Treatment Failure | 2 | 2017 | 2656 | 0.030 |
Why?
|
Thrombin | 1 | 1997 | 600 | 0.030 |
Why?
|
Incidence | 3 | 2021 | 21552 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2013 | 6242 | 0.030 |
Why?
|
Spiral Cone-Beam Computed Tomography | 1 | 2015 | 32 | 0.030 |
Why?
|
Immunotherapy | 2 | 2021 | 4728 | 0.030 |
Why?
|
Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
CA-19-9 Antigen | 1 | 2014 | 107 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2015 | 2834 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 167 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 22386 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 270 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2013 | 513 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1600 | 0.030 |
Why?
|
Intestine, Large | 1 | 2012 | 69 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2727 | 0.020 |
Why?
|
United States | 4 | 2023 | 73121 | 0.020 |
Why?
|
Liver Function Tests | 1 | 2013 | 527 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2014 | 2884 | 0.020 |
Why?
|
Administration, Oral | 2 | 2011 | 4041 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2010 | 3520 | 0.020 |
Why?
|
Glutamic Acid | 1 | 1997 | 1192 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2013 | 882 | 0.020 |
Why?
|
Length of Stay | 2 | 2019 | 6521 | 0.020 |
Why?
|
Brachytherapy | 1 | 2019 | 1227 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 3 | 2015 | 5709 | 0.020 |
Why?
|
Genes, ras | 1 | 2014 | 666 | 0.020 |
Why?
|
GPI-Linked Proteins | 1 | 2013 | 473 | 0.020 |
Why?
|
Hydroxyestrones | 1 | 2010 | 17 | 0.020 |
Why?
|
Adolescent | 4 | 2023 | 89168 | 0.020 |
Why?
|
Genotype | 2 | 2017 | 13047 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15460 | 0.020 |
Why?
|
Time Factors | 4 | 2015 | 40271 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 2010 | 372 | 0.020 |
Why?
|
Urogenital System | 1 | 2010 | 88 | 0.020 |
Why?
|
Neoplasm Proteins | 2 | 2013 | 3611 | 0.020 |
Why?
|
Defecation | 1 | 2012 | 191 | 0.020 |
Why?
|
Lymphatic Irradiation | 1 | 2010 | 115 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3063 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 906 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 560 | 0.020 |
Why?
|
Diphosphonates | 1 | 2014 | 635 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2013 | 679 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2013 | 2228 | 0.020 |
Why?
|
Failure to Thrive | 1 | 2009 | 140 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 130 | 0.020 |
Why?
|
Risk Factors | 3 | 2014 | 74915 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 1998 | 6320 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7213 | 0.020 |
Why?
|
Patient Dropouts | 1 | 2010 | 411 | 0.020 |
Why?
|
Endoscopy, Digestive System | 1 | 2011 | 354 | 0.020 |
Why?
|
Cause of Death | 1 | 2019 | 3727 | 0.020 |
Why?
|
Cytarabine | 1 | 2010 | 697 | 0.020 |
Why?
|
Drug Substitution | 1 | 2010 | 291 | 0.020 |
Why?
|
Radiotherapy, Conformal | 1 | 2011 | 549 | 0.020 |
Why?
|
Prescriptions | 1 | 2010 | 387 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2014 | 8635 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2009 | 457 | 0.020 |
Why?
|
Lung Neoplasms | 2 | 2003 | 13589 | 0.020 |
Why?
|
Intestinal Obstruction | 1 | 2011 | 435 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2014 | 7895 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5532 | 0.020 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1176 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2010 | 499 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1643 | 0.020 |
Why?
|
Nausea | 1 | 2009 | 682 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7246 | 0.020 |
Why?
|
Vomiting | 1 | 2009 | 655 | 0.020 |
Why?
|
Radiology Department, Hospital | 1 | 2010 | 409 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7863 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3955 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1307 | 0.020 |
Why?
|
Pregnancy | 1 | 2008 | 30179 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2011 | 2126 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8730 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5880 | 0.020 |
Why?
|
Postoperative Period | 1 | 2010 | 1833 | 0.020 |
Why?
|
Taxoids | 1 | 2009 | 669 | 0.020 |
Why?
|
Efficiency, Organizational | 1 | 2010 | 699 | 0.020 |
Why?
|
Diarrhea | 1 | 2012 | 1320 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2013 | 3637 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 2003 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2019 | 12450 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2010 | 840 | 0.010 |
Why?
|
Lymph Node Excision | 1 | 2010 | 1276 | 0.010 |
Why?
|
Nurses | 1 | 2014 | 2494 | 0.010 |
Why?
|
Disease Management | 1 | 2015 | 2533 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2863 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2013 | 15965 | 0.010 |
Why?
|
Piperidines | 1 | 2012 | 1664 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2011 | 1126 | 0.010 |
Why?
|
Documentation | 1 | 2010 | 913 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14766 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 1998 | 8051 | 0.010 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2005 | 622 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2000 | 5426 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2019 | 4877 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 2006 | 878 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20231 | 0.010 |
Why?
|
Hepatitis B virus | 1 | 2005 | 530 | 0.010 |
Why?
|
Caregivers | 1 | 2014 | 2302 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4077 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8373 | 0.010 |
Why?
|
Radiotherapy, High-Energy | 1 | 2000 | 228 | 0.010 |
Why?
|
Risk Assessment | 2 | 2013 | 24311 | 0.010 |
Why?
|
Logistic Models | 1 | 2014 | 13324 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 13030 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2009 | 3234 | 0.010 |
Why?
|
Recurrence | 1 | 2011 | 8510 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 17149 | 0.010 |
Why?
|
Kringles | 1 | 1997 | 8 | 0.010 |
Why?
|
Palliative Care | 1 | 2013 | 3644 | 0.010 |
Why?
|
Sex Factors | 1 | 2012 | 10647 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9507 | 0.010 |
Why?
|
Virus Replication | 1 | 2005 | 2459 | 0.010 |
Why?
|
New England | 1 | 2000 | 1056 | 0.010 |
Why?
|
Signal Transduction | 2 | 2011 | 23638 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3538 | 0.010 |
Why?
|
Risk | 1 | 2008 | 9642 | 0.010 |
Why?
|
Prevalence | 1 | 2013 | 15880 | 0.010 |
Why?
|
Disulfides | 1 | 1997 | 467 | 0.010 |
Why?
|
CHO Cells | 1 | 1997 | 1382 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2010 | 4340 | 0.010 |
Why?
|
Comorbidity | 1 | 2009 | 10601 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1997 | 1688 | 0.010 |
Why?
|
Cricetinae | 1 | 1997 | 2423 | 0.010 |
Why?
|
Pneumonectomy | 1 | 2000 | 1159 | 0.010 |
Why?
|
Protein Precursors | 1 | 1997 | 1133 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 10784 | 0.010 |
Why?
|
Contrast Media | 1 | 2006 | 5336 | 0.010 |
Why?
|
Animals | 2 | 2022 | 169418 | 0.010 |
Why?
|
Ultrasonography | 1 | 2005 | 5995 | 0.010 |
Why?
|
Hospitalization | 1 | 2011 | 10845 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2008 | 22293 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 1997 | 3735 | 0.000 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 18048 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1997 | 13452 | 0.000 |
Why?
|
Peptide Fragments | 1 | 1997 | 5152 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1997 | 17647 | 0.000 |
Why?
|